NCT01108783View on ClinicalTrials.gov

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

PHASE3CompletedINTERVENTIONAL

Enrollment

720

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

August 31, 2003

Study Completion Date

February 29, 2004

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Bilastine

20 mg (encapsulated) tablets QD/14 days

DRUG

Desloratadine

5 mg (encapsulated) tablets QD/14 days

DRUG

Placebo

(encapsulated) Tablets QD/14 days

Sponsors

Lead Sponsor

Faes Farma, S.A.

All Listed Sponsors

lead

Faes Farma, S.A.

INDUSTRY

NCT01108783 - A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine | Biotech Hunter | Biotech Hunter